| Vol. 16.11 – 21 March, 2024 |
| |
|
|
| Scientists reported that a lectin-based thermophoretic assay streamlined vibrating membrane filtration and thermophoretic amplification, allowing for rapid, sensitive, selective, and cost-effective extracellular vesicle glycan profiling in TNBC plasma. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Among the hyperactive candidate transcription factors of basal-like breast cancer (BLBC) identified by bioinformatic analysis, POU4F1 was uniquely upregulated in BLBC and was associated with poor prognosis. [Advanced Science] |
|
|
|
| Using novel multi-compartment organoids and multiple in vivo models, investigators showed that E-cadherin promoted a hyper-proliferative phenotype in breast cancer cells via interaction with the transmembrane receptor EGFR. [Oncogene] |
|
|
|
| Linc00707 promoted TNBC cell proliferation, migration, and invasion. Knockdown of Linc00707 influenced autophagy via PI3K/AKT/mTOR signaling pathway in TNBC cells. [Cell Death Discovery] |
|
|
|
| Investigators assessed the expression of miR-425-5p and its target monocarboxylate transporter (MCT4) in breast cancer associated fibroblasts and normal fibroblasts. [Cell Death Discovery] |
|
|
|
| The effects of M-protein on the ability of extracellular vesicles derived from TNBC cells to regulate the functions of tissue stem cells facilitating the tumor microenvironment were examined. [Frontiers In Oncology] |
|
|
|
|
| The authors focus on the effect of mitochondria movement on breast cancer progression. [Clinical & Experimental Metastasis] |
|
|
|
|
| Puma Biotechnology, Inc. was notified by the US FDA that its investigational new drug application submission has been reviewed, and they can proceed with the clinical development of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer. [Puma Biotechnology, Inc.] |
|
|
|
|
|
|
|
| Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
| Montreal Clinical Research Institute – Montréal, Québec, Canada |
|
|
|
|